| Ident. | Authors (with country if any) | Title |
|---|
| 000000 |
Alexandro Gianforcaro [Canada] ; Mazen J. Hamadeh [Canada] | Vitamin D as a Potential Therapy in Amyotrophic Lateral Sclerosis |
| 000005 |
Michel Panisset [Canada] ; Jack J. Chen [États-Unis] ; Sean H. Rhyee [États-Unis] ; Jill Conner [États-Unis] ; Julie Mathena [États-Unis] | Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO) |
| 000006 |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
| 000043 |
Roger S. Mcintyre [Canada] ; Alissa M. Powell [Canada] ; Oksana Kaidanovich-Beilin [Canada] ; Joanna K. Soczynska [Canada] ; Mohammad Alsuwaidan [Canada] ; Hanna O. Woldeyohannes [Canada] ; Ashley S. Kim [Canada] ; L. Ashley Gallaugher [Canada] | The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders |
| 000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 000049 |
Nir Lipsman [Canada] ; D. Blake Woodside [Canada] ; Peter Giacobbe [Canada] ; Clement Hamani [Canada] ; Jacqueline C. Carter [Canada] ; Sarah Jane Norwood [Canada] ; Kalam Sutandar [Canada] ; Randy Staab [Canada] ; Gavin Elias [Canada] ; Christopher H. Lyman [États-Unis] ; Gwenn S. Smith [États-Unis] ; Andres M. Lozano [Canada] | Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial |
| 000060 |
Abdul Qayyum Rana [Canada] ; Ishraq Siddiqui [Canada] ; Masood Zangeneh [Canada] ; Abdul Fattah [Canada] ; Naeem Awan [Canada] ; Muhammad Saad Yousuf [Canada] | Predicting treatment-seeking for visual hallucinations among Parkinson's disease patients |
| 000065 |
Susan H. Fox [Canada] | Non-dopaminergic Treatments for Motor Control in Parkinson's Disease |
| 000068 |
Danielle Murray [Canada] ; A. Jon Stoessl [Canada] | Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions |
| 000128 |
Chaim M. Bell [Canada] ; Stacey S. Brener [Canada] ; Rebecca Comrie [Canada] ; Geoffrey M. Anderson [Canada] ; Susan E. Bronskill [Canada] | Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process |
| 000142 |
Maria C. Rodriguez-Oroz [Espagne] ; Elena Moro [Canada] ; Paul Krack [France] | Long-Term Outcomes of Surgical Therapies for Parkinson's Disease |
| 000145 |
Alan C. Jackson [Canada] | Is minocycline useful for therapy of acute viral encephalitis? |
| 000169 |
Yusuke Iwata [Japon] ; Sachiko Irie [Japon] ; Hiroyuki Uchida [Japon, Canada] ; Takefumi Suzuki [Japon] ; Koichiro Watanabe [Japon] ; Satoru Iwashita [Japon] ; Masaru Mimura [Japon] | Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial |
| 000190 |
Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] ; Renato P. Munhoz [Brésil] ; Katia Charland [Canada] ; Amelie Pelletier [Canada] ; Mariana Moscovich [Brésil] ; Luciane Filla [Brésil] ; Debora Zanatta [Brésil] ; Silvia Rios Romenets [Canada] ; Robert Altman [Canada] ; Rosa Chuang [Canada] ; Binit Shah [Canada] | Caffeine for treatment of Parkinson disease: A randomized controlled trial |
| 000215 |
Penny A. Macdonald [Canada] ; Alex A. Macdonald [Canada] ; Ken N. Seergobin [Canada] ; Ruzbeh Tamjeedi [Canada] ; Hooman Ganjavi [Canada] ; Jean-Sebastien Provost [Canada] ; Oury Monchi [Canada] | The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI |
| 000217 |
Klaus Seppi ; Daniel Weintraub ; Miguel Coelho ; Santiago Perez-Lloret ; Susan H. Fox ; Regina Katzenschlager ; Eva-Maria Hametner ; Werner Poewe [Autriche] ; Olivier Rascol ; Christopher G. Goetz ; Cristina Sampaio | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease |
| 000218 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease |
| 000225 |
Amit Bar-Or [Canada] ; Peter Rieckmann [Canada] ; Anthony Traboulsee [Canada] ; V. Wee Yong [Canada] | Targeting Progressive Neuroaxonal Injury: Lessons from Multiple Sclerosis |
| 000228 |
Diego Santos-Garcia [Espagne] ; Mercedes Macias [Espagne] ; Miguel Llaneza [Espagne] ; M Nica Grande [Espagne] ; Raúl De La Fuente-Fernandez [Canada] | Serum Vitamin B12 and Folate Levels in Parkinson's Disease Patients Treated with Duodenal Levodopa Infusion |
| 000235 |
Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada] | Predictors of Time to Requiring Dopaminergic Treatment in 2 Parkinson's Disease Cohorts |
| 000237 |
C. Gibrat [Canada] ; F. Cicchetti [Canada] | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases : THE NEUROBIOLOGY OF NEURODEGENERATIVE DISORDER: FROM BASIC TO CLINICAL RESEARCH |
| 000253 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
| 000268 |
Kaitlyn P. Roland [Canada] ; Jennifer M. Jakobi [Canada] ; Colin Powell [Canada] ; Gareth R. Jones [Canada] | Factors related to functional independence in females with Parkinson's disease: A systematic review |
| 000275 |
Lori-Ann R. Sacrey [Canada] ; Scott G. Travis [Canada] ; Ian Q. Whishaw [Canada] | Drug treatment and familiar music aids an attention shift from vision to somatosensation in Parkinson's disease on the reach-to-eat task |
| 000294 |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Ilona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Therese Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials |
| 000317 |
T. A. Zesiewicz [États-Unis] ; K. L. Sullivan [États-Unis] ; I. Arnulf [France] ; K. R. Chaudhuri [Royaume-Uni] ; J. C. Morgan [États-Unis] ; G. S. Gronseth [États-Unis] ; J. Miyasaki [Canada] ; D. J. Iverson [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology |
| 000340 |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [États-Unis] | Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD Study |
| 000345 |
Rodger J. Elble [États-Unis] ; Oksana Suchowersky [Canada] ; Stephanie Shaftman [Canada, États-Unis] ; William J. Weiner [États-Unis] ; PENG HUANG [États-Unis] ; Barbara Tilley [États-Unis] | Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease |
| 000356 |
Janis M. Miyasaki [Canada] | Evidence-based initiation of dopaminergic therapy in Parkinson's disease |
| 000361 |
Bazoumana Ouattara [Canada] ; Fabrizio Gasparini [Suisse] ; Marc Morissette [Canada] ; Laurent Gregoire [Canada] ; Pershia Samadi [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Thérèse Di Paolo [Canada] | Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys |
| 000370 |
Edeltraut Kröger [Pays-Bas, Canada] ; Rob Van Marum [Pays-Bas] ; Patrick Souverein [Pays-Bas] ; Toine Egberts [Pays-Bas] | Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands: A Retrospective Cohort Study |
| 000378 |
Emmanuelle Pourcher [Canada, France] ; Sophie Remillard [Canada] ; Henri Cohen [Canada, France] | Compulsive habits in restless legs syndrome patients under dopaminergic treatment |
| 000379 |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew J. Lees [Royaume-Uni] | Compulsive Use of Dopaminergic Drug Therapy in Parkinson's Disease: Reward and Anti-Reward |
| 000402 |
Anthony E. Lang [Canada] | When and how should treatment be started in Parkinson disease? |
| 000411 |
WEI SONG [Canada] ; Amar Patel [Canada] ; Hamid Y. Qureshi [Canada] ; DONG HAN [Canada] ; Hyman M. Schipper [Canada] ; Hemant K. Paudel [Canada] | The Parkinson disease-associated A30P mutation stabilizes α-synuclein against proteasomal degradation triggered by heme oxygenase-1 over-expression in human neuroblastoma cells |
| 000422 |
S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France] | Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide |
| 000448 |
Oliver Cooper [États-Unis] ; Arnar Astradsson [États-Unis] ; Penny Hallett [États-Unis] ; Harold Robertson [Canada] ; Ivar Mendez [Canada] ; Ole Isacson [États-Unis] | Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients |
| 000475 |
Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse] | Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease |
| 000481 |
Claire Gibrat [Canada] ; Martine Saint-Pierre [Canada] ; Mélanie Bousquet [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Francesca Cicchetti [Canada] | Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions |
| 000489 |
A. W. Zuardi [Brésil] ; J. A. S. Crippa [Brésil] ; J. E. C. Hallak [Brésil] ; J. P. Pinto [Brésil] ; M. H. N. Chagas [Brésil] ; G. G. R. Rodrigues [Brésil] ; S. M. Dursun [Canada] ; V. Tumas [Brésil] | Cannabidiol for the treatment of psychosis in Parkinson's disease |
| 000499 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts |
| 000505 |
Patrick Fitzgerald [Irlande (pays)] ; Arkady Mandel [Canada] ; Anthony E. Bolton [Irlande (pays)] ; Aideen M. Sullivan [Irlande (pays)] ; Yvonne Nolan [Irlande (pays)] | Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease |
| 000514 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
| 000536 |
Clement Hamani [Canada] ; Elena Moro [Canada] ; Cindy Zadikoff [Canada] ; Yu-Yan Poon [Canada] ; Andres M. Lozano [Canada] ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay ; Robert G. Grossman | LOCATION OF ACTIVE CONTACTS IN PATIENTS WITH PRIMARY DYSTONIA TREATED WITH GLOBUS PALLIDUS DEEP BRAIN STIMULATION |
| 000548 |
Behnam A. Baghbaderani [Canada] ; Leo A. Behie [Canada] ; Arindom Sen [Canada] ; Karim Mukhida [Canada] ; Murray Hong [Canada] ; Ivar Mendez [Canada] | Expansion of Human Neural Precursor Cells in Large-Scale Bioreactors for the Treatment of Neurodegenerative Disorders |
| 000570 |
Maria Fraraccio [Canada] ; Alain Ptito [Canada] ; Abbas Sadikot [Canada] ; Michel Panisset [Canada] ; Alain Dagher [Canada] | Absence of cognitive deficits following deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease |
| 000573 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Wemer Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a Disease Modifying Therapy in Parkinson's Disease (The ADAGIO Study) : Rationale, Design, and Baseline Characteristics |
| 000580 |
Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | The role of anti-inflammatory agents in Parkinson's disease |
| 000581 |
Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | The role of anti-inflammatory agents in Parkinson's disease |
| 000591 |
Moigan Hodaie [Canada] ; Joseph S. Neimat [États-Unis] ; Andres M. Lozano [Canada] ; Erik C. Parker ; Patrick J. Kelly ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay | The dopaminergic nigrostriatal system and Parkinson's disease : Molecular events in development, disease, and cell death, and new therapeutic strategies. Commentary |
| 000592 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
| 000604 |
A. Jon Stoessl [Canada] ; Michael G. Kaplitt [États-Unis] ; Andrew Feigin [États-Unis] ; Chengke Tang [États-Unis] ; Helen L. Fitzsimons ; Paul Mattis [États-Unis] ; Patricia A. Lawlor [Nouvelle-Zélande] ; Ross J. Bland ; Deborah Young [Nouvelle-Zélande] ; Kristin Strybing [États-Unis] ; David Eidelberg [États-Unis] ; Matthew J. During [États-Unis, Nouvelle-Zélande] | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease : an open label, phase I trial. Commentary |
| 000612 |
Janis M. Miyasaki [Canada] ; Khalid Al Hassan [Canada] ; Anthony E. Lang [Canada] ; Valerie Voon [Canada] | Punding prevalence in Parkinson's disease |
| 000616 |
Timothy I. Morgenthaler [États-Unis] ; Vishesh K. Kapur [États-Unis] ; Terry Brown [États-Unis] ; Todd J. Swick [États-Unis] ; Cathy Alessi [États-Unis] ; R. Nisha Aurora [États-Unis] ; Brian Boehlecke [États-Unis] ; Andrew L. Jr Chesson [États-Unis] ; Leah Friedman [États-Unis] ; Rama Maganti [États-Unis] ; Judith Owens [États-Unis] ; Jeffrey Pancer ; Rochelle Zak [États-Unis] | Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin : An American Academy of Sleep Medicine Report |
| 000623 |
Rohita Sharma [Canada] ; Catherine R. Mcmillan [Canada] ; Lennard P. Niles [Canada] | Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease |
| 000626 |
Alexandre Berney [Canada, Suisse] ; Michel Panisset [Canada] ; Abbas F. Sadikot [Canada] ; Alain Ptito [Canada] ; Alain Dagher [Canada] ; Maria Fraraccio [Canada] ; Ghislaine Savard [Canada] ; Marc Pell [Canada] ; Chawki Benkelfat [Canada] | Mood Stability during Acute Stimulator Challenge in Parkinson's Disease Patients Under Long-Term Treatment with Subthalamic Deep Brain Stimulation |
| 000640 |
Teri R. Thomsen [Canada] ; Wendy R. Galpem [Canada] ; Abena Asante [Canada] ; Tamara Arenovich [Canada] ; Susan H. Fox [Canada] | Ipratropium Bromide Spray as Treatment for Sialorrhea in Parkinson's Disease |
| 000654 |
Philippe Huot [Canada] ; André Parent [Canada] | Dopaminergic neurons intrinsic to the striatum |
| 000661 |
Nir Lipsman [Canada] ; Joseph S. Neimat [États-Unis] ; Andres M. Lozano [Canada] ; Philip L. Gildenberg ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay ; Bjorn A. Meyerson ; Brian H. Kopell ; Ali R. Rezai | Deep brain stimulation for treatment-refractory obsessive-compulsive disorder : The search for a valid target. Commentary |
| 000675 |
Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 000680 |
James Scozzafava [Canada] ; Jennifer Takahashi [Canada] ; Wendy Johnston [Canada] ; Lakshmi Puttagunta [Canada] ; W. R. Wayne Martin [Canada] | Valvular heart disease in pergolide- treated Parkinson's disease |
| 000683 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
| 000697 |
J. Miklossy [Canada] ; D. D. Doudet [Canada] ; C. Schwab [Canada] ; S. Yu [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Role of ICAM-1 in persisting inflammation in parkinson disease and MPTP monkeys |
| 000703 |
R. Pahwa [États-Unis] ; S. A. Factor [États-Unis] ; K. E. Lyons [États-Unis] ; W. G. Ondo [États-Unis] ; G. Gronseth [États-Unis] ; H. Bronte-Stewart [États-Unis] ; M. Hallett [États-Unis] ; J. Miyasaki [Canada] ; J. Stevens [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000704 |
O. Suchowersky [Canada] ; G. Gronseth [États-Unis] ; J. Perlmutter [États-Unis] ; S. Reich [États-Unis] ; T. Zesiewicz [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000705 |
J. M. Miyasaki [Canada] ; K. Shannon [États-Unis] ; V. Voon [États-Unis] ; B. Ravina [États-Unis] ; G. Kleiner-Fisman [États-Unis] ; K. Anderson [États-Unis] ; L. M. Shulman [États-Unis] ; G. Gronseth [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Evaluation and treatment of depression, psychosis, and dementia in parkinson disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000722 |
Meenal Joshi [Canada] ; Rachel F. Tyndale [Canada] | Induction and recovery time course of rat brain CYP2E1 after nicotine treatment |
| 000724 |
Zoran Todorovic [Serbie] ; Eleonora Dzoljic [Serbie] ; Ivana Novakovic [Serbie] ; Dusko Mirkovic [Serbie] ; Radan Stojanovic [Serbie] ; Zorica Nesic [Serbie] ; Maja Krajinovic [Canada] ; Milica Prostran [Serbie] ; Vladimir Kostic [Serbie] | Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy |
| 000732 |
Charles Ramassamy [Canada] | Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases : A review of their intracellular targets |
| 000734 |
Andrew R. Willan [Canada] ; Ron Goeree [Canada] ; Eleanor M. Pullenayegum [Canada] ; Christopher Mcburney [États-Unis] ; Gordon Blackhouse [Canada] | Economic evaluation of rivastigmine in patients with parkinson's disease dementia |
| 000744 |
Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis] | Crossroads in GDNF therapy for Parkinson's disease |
| 000747 |
Maryka Quik [États-Unis] ; Neeraja Parameswaran [États-Unis] ; Sarah E. Mccallum [États-Unis] ; Tanuja Bordia [États-Unis] ; SHANSHAN BAO [États-Unis] ; Alison Mccormack [États-Unis] ; Amy Kim [États-Unis] ; Rachel F. Tyndale [Canada] ; J. William Langston [États-Unis] ; Donato A. Di Monte [États-Unis] | Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates |
| 000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000785 |
Guy Chouinard [Canada] ; Howard C. Margolese [Canada] | Manual for the Extrapyramidal Symptom Rating Scale (ESRS) |
| 000822 |
Brad Hagen [Canada] ; Chris Armstrong Esther [Canada] ; Roland Ikuto [Canada] ; Robert J. Williams [Canada] ; Carole-Lynne Le Navenec [Canada] ; Morgan Aho | Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation |
| 000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
| 000830 |
Colleen P. Millikin [Canada] ; Lisa L. Trepanier [Canada] ; Sean B. Rourke [Canada] | Verbal fluency component analysis in adults with HIV/AIDS |
| 000832 |
Jason A. Brodkey [Canada] ; Ronald R. Tasker ; Clement Hamani ; Mary Pat Mcandrews ; Jonathan O. Dostrovsky ; Andres M. Lozano | Tremor cells in the human thalamus: differences among neurological disorders |
| 000847 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000854 |
Ajmal Razmy [Canada] ; Anthony E. Lang [Canada] ; Colin M. Shapiro [Canada] | Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists |
| 000862 |
Yoanna K. Skrobik [Canada] ; Nicolas Bergeron [Canada] ; Marc Dumont [Canada] ; Stewart B. Gottfried [Canada] | Olanzapine vs haloperidol: treating delirium in a critical care setting |
| 000867 |
Martin Zonenshayn [États-Unis] ; Djordje Sterio [États-Unis] ; Patrick J. Kelly [États-Unis] ; Ali R. Rezai [États-Unis] ; Aleksander Beric [États-Unis] ; Kim J. Burchiel [États-Unis] ; Ronald R. Tasker [Canada] | Location of the active contact within the subthalamic nucleus (STN) in the treatment of idiopathic Parkinson's disease. Commentary |
| 000869 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio ; Fabrizio Stocchi | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 000873 |
Frédéric Calon [Canada] ; Mehdi Dridi [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada] | Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias |
| 000874 |
Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] | Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy? |
| 000875 |
Mark D. Berry [Canada] | Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders |
| 000879 |
Lynsey E. Bartlett [Canada] ; Damaso Sadi [Canada] ; Matthew Lewington [Canada] ; Ivar Mendez [Canada] ; Nicholas M. Boulis ; Charles Y. Liu ; Andres M. Lozano ; Roy A. E. Bakay | Functional improvement with low-dose dopaminergic grafts in hemiparkinsonian rats. Comments |
| 000903 |
Ajit Kumar [Canada] ; Sharanpal Mann [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Michael Schulzer [Canada] ; Chong S. Lee [Canada] | [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease |
| 000907 |
Joseph King Ching Tsui [Canada] | Treatment of dystonia in Parkinson's disease |
| 000908 |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
| 000912 |
Andres M. Lozano [Canada] | Surgery for Parkinson's disease, the five W's: Why, who, what, where, and when |
| 000916 |
Aviva Abosch [Canada] ; Andres Lozano [États-Unis] | Stereotactic neurosurgery for movement disorders |
| 000920 |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
| 000922 |
J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis] | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD |
| 000926 |
Patrick L. Mcgeer [Canada] ; Claudia Schwab [Canada] ; Andre Parent [Canada] ; Doris Doudet [Canada] | Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration |
| 000927 |
Simon Lemay [Canada] ; Pierre Blanchet [Canada] ; Sylvain Chouinard [Canada] ; Hélène Masson [Canada] ; Valérie Soland [Canada] ; Marc-André Bedard [Canada] | Poor tolerability of a transdermal nicotine treatment in Parkinson's disease |
| 000937 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 000938 |
Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada] | Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease |
| 000941 |
Ajit Kumar [Canada] ; ZHIGAO HUANG [Canada] ; Raul De La Fuente-Fernandez [Canada] | Mechanisms of motor complications in treatment of Parkinson's disease |
| 000942 |
Douglas Coyle [Canada] ; Martin J. Buxton [Royaume-Uni] ; Bernie J. O'Brien [Canada] | Measures of importance for economic analysis based on decision modeling |
| 000945 |
Galit Kleiner-Fisman [Canada] ; David N. Fisman ; Elspeth Sime ; Jean A. Saint-Cyr ; Andres M. Lozano ; Anthony E. Lang | Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease |
| 000951 |
Adam O. Hebb [Canada] ; Kari Hebb ; Arun C. Ramachandran ; Ivar Mendez | Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage |
| 000952 |
Yoshiaki Furukawa [Canada] | Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss |
| 000965 |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
| 000966 |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
| 000967 |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
| 000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000975 |
D. J. Brooks [Royaume-Uni] ; K. A. Frey [États-Unis] ; K. L. Marek [États-Unis] ; D. Cakes [États-Unis] ; D. Paty [Canada] ; R. Prentice [États-Unis] ; C. W. Shults [États-Unis] ; A. J. Stoessl [Canada] | Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease |
| 000979 |
C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis] | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's Disease |
| 000984 |
Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
| 000985 |
B. D. Westerberg [Canada] ; J. B. Roberson [États-Unis] ; B. A. Stach [Canada] ; G. D. Silverberg [États-Unis] ; G. Heit [États-Unis] | The effects of posteroventral pallidotomy on balance function in patients with Parkinson's disease |
| 000987 |
H. Christopher Hyson [Canada] ; Andrew M. Johnson [Canada] ; Mandar S. Jog [Canada] | Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study |
| 000991 |
Ivar Mendez [Canada] ; Alain Dagher ; Murray Hong ; Paula Gaudet ; Swarna Weerasinghe ; Vivian Mcalister ; David King ; Jacques Desrosiers ; Sultan Darvesh ; Tanya Acorn ; Harold Robertson | Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study: Report of three cases |
| 000997 |
M. Guttman [Canada] ; P. M. Slaughter [Canada] ; M.-E. Theriault [Canada] ; D. P. Deboer [Canada] ; C. D. Naylor [Canada] | Parkinsonism in Ontario: Physician utilization |
| 000A02 |
Z. H. T. Kiss [Canada] ; D. M. Mooney [Canada] ; L. Renaud [Canada] ; B. Hu [Canada] | Neuronal response to local electrical stimulation in rat thalamus: Physiological implications for mechanisms of deep brain stimulation |
| 000A07 |
Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] | Mechanisms of deep brain stimulation |
| 000A18 |
Stefan Müller-Lissner [Allemagne] | General geriatrics and gastroenterology: constipation and faecal incontinence |
| 000A29 |
C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
| 000A33 |
Anthony E. Lang [Canada] ; Hakan Widner [Suède] | Deep brain stimulation for Parkinson's disease: Patient selection and evaluation |
| 000A37 |
Nicole Duchesne [Canada] ; Jean-Paul Soucy [Canada] ; Hélène Masson [Canada] ; Sylvain Chouinard [Canada] ; Marc-André Bedard [Canada] | Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients on and OFF levodopa |
| 000A51 |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study |
| 000A58 |
Lauri V. Laitinen [Suède] | Surgical treatment for Parkinson's disease over the last decade |
| 000A59 |
C. Warren Olanow [États-Unis] ; Mitchell F. Brin [États-Unis] | Surgical therapies for Parkinson's disease: A physician's perspective |
| 000A65 |
Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Daniel Levesque [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model |
| 000A66 |
Erik Ch. Wolters [Pays-Bas] | Psychiatric complications in the treatment of Parkinson's disease |
| 000A69 |
Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] | Pallidotomy for Parkinson's disease |
| 000A70 |
Ahmed Alkhani [Canada] ; Andres M. Lozano [Canada] | Pallidotomy for Parkinson disease : a review of contemporary literature |
| 000A74 |
Thomas B. Freeman [États-Unis] ; Allison Willing [États-Unis] ; Tanya Zigova [États-Unis] ; Paul R. Sanberg [États-Unis] ; Robert A. Hauser [États-Unis] | Neural transplantation in Parkinson's disease |
| 000A78 |
Doris J. Doudet [Canada] | Monitoring disease progression in Parkinson's disease |
| 000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000A83 |
A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada] | Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats |
| 000A84 |
Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
| 000A87 |
M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada] | Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD |
| 000A89 |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
| 000A92 |
Ole Isacson [États-Unis] ; Craig Van Horne [États-Unis] ; James M. Schumacher [États-Unis] ; Anna-Liisa Brownell [États-Unis] | Improved surgical cell therapy in Parkinson's disease: Physiological basis and new transplantation methodology |
| 000B03 |
John G. Nutt [États-Unis] | Fluctuations in response to treatment for Parkinson's disease |
| 000B07 |
Raul De La Fuente-Fernandez [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease |
| 000B15 |
Moussa B. H. Youdim [Israël] ; Edna Grünblatt [Israël] ; Yona Levites-Royak [Israël] ; Silvia Mandel [Israël] | Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expression |
| 000B17 |
Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France] | Dopamine agonists: Their role in the management of Parkinson's disease |
| 000B25 |
Hiroshi Ichinose [Japon] ; Takahiro Suzuki [Japon] ; Hidehito Inagaki [Japon] ; Tamae Ohye [Japon] ; Toshiharu Nagatsu [Japon] | DOPA-responsive dystonia: From causative gene to molecular mechanism |
| 000B26 |
Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
| 000B31 |
Heikki Ter V Inen [Finlande] ; Urpo Rinne [Finlande] ; Ariel Gordin [Finlande] | Catechol-O-methyltransferase inhibitors in Parkinson's disease |
| 000B32 |
Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
| 000B33 |
Marco Scarselli [Italie] ; Marianna Armogida [Italie] ; Carla Pardini [Italie] ; Serena Chiacchio [Italie] ; Giovanni U. Corsini [Italie] | Apomorphine: A novel effect for an old compound |
| 000B35 |
Lana Depatie [Canada] ; Samarthji Lal [Canada] | Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? |
| 000B36 |
Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
| 000B43 |
R. Kumar [Canada] ; A. E. Lang [Canada] ; M. C. Rodriguez-Oroz [Espagne] ; A. M. Lozano [Canada] ; P. Limousin [France] ; P. Pollak [France] ; A. L. Benabid [France] ; J. Guridi [Espagne] ; E. Ramos [Espagne] ; C. Van Der Linden [Belgique] ; A. Vandewalle [Belgique] ; J. Caemaert [Belgique] ; E. Lannoo [Belgique] ; D. Van Den Abbeele [Belgique] ; G. Vingerhoets [Belgique] ; M. Wolters [Belgique] ; J. A. Obeso [Espagne] | eep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease |
| 000B44 |
Y. L. Xue [République populaire de Chine] ; Z. F. Wang [République populaire de Chine] ; D. G. Zhong [République populaire de Chine] ; X. Cui [République populaire de Chine] ; X. J. Li [République populaire de Chine] ; X. J. Ma [République populaire de Chine] ; L. N. Wang [République populaire de Chine] ; K. Zhu [République populaire de Chine] ; A. M. Sun [Canada] | Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys |
| 000B46 |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
| 000B52 |
J. Guridi [Espagne] ; M. C. Rodriguez-Oroz [Espagne] ; A. M. Lozano [Canada] ; E. Moro [Italie] ; A. Albanese [Italie] ; B. Nuttin [Belgique] ; J. Gybels [Belgique] ; E. Ramos [Espagne] ; J. A. Obeso [Espagne] | Targeting the basal ganglia for deep brain stimulation in Parkinson's disease |
| 000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
| 000B54 |
A. E. Lang [Canada] ; LANGSTON ; RASCOL ; BROTCHIE ; BENABID ; MELAMED ; BONUCELLI ; OLANOW ; OBESO ; GIMENEZ-ROLDAN ; RAJPUT ; FAHN ; NUTT ; BROOKS ; CHASE | Surgery for levodopa-induced dyskinesias. Discussion |
| 000B55 |
A. E. Lang [Canada] | Surgery for Parkinson disease : A critical evaluation of the state of the art |
| 000B59 |
W. J. Lombardi [États-Unis, Canada] ; R. E. Gross [États-Unis, Canada] ; L. L. Trepanier [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] ; J. A. Saint-Cyr [Canada] | Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum |
| 000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 000B62 |
C. R. Honey [Canada] ; M. O. K. Obochi ; HAO SHEN ; P. Margaron ; S. Yip ; J. G. Levy | Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts |
| 000B76 |
P. Ashby [Canada] ; J. C. Rothwell [Royaume-Uni] | Neurophysiologic aspects of deep brain stimulation |
| 000B78 |
I. Mendez [Canada] ; M. Hong ; S. Smith ; A. Dagher ; J. Desrosiers | Neural transplantation cannula and microinjector system : experimental and clinical experience : Technical note |
| 000B82 |
M. N. Linhares [Canada] ; R. R. Tasker [Canada] ; R. A. E. Bakay ; K. J. Burchiel ; P. J. Kelly | Microelectrode-guided thalamotomy for Parkinson's Disease. Commentary |
| 000B84 |
P. K. Pal [Canada] ; A. Samii [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; I. M. Turnbull [Canada] ; D. B. Calne [Canada] | Long term outcome of unilateral pallidotomy : Follow up of 15 patients for 3 years |
| 000B86 |
K. A. Baker [Canada] ; M. Hong [Canada] ; D. Sadi [Canada] ; I. Mendez [Canada] | Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease |
| 000B93 |
I. Mendez [Canada] ; A. Dagher ; M. Hong ; A. Hebb ; P. Gaudet ; A. Law ; S. Weerasinghe ; D. King ; J. Desrosiers ; S. Darvesh ; T. Acorn ; H. Robertson | Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease : Report of two cases and technical considerations |
| 000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| 000B96 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 000C03 |
P. K. Pal [Canada] ; D. B. Calne [Canada] ; S. Calne [Canada] ; J. K. C. Tsui [Canada] | Botulinum toxin A as treatment for drooling saliva in PD |
| 000C06 |
T. J. Hudzik [États-Unis] ; A. Howell [États-Unis] ; K. Payza [Canada] ; A. J. Cross [États-Unis] | Antiparkinson potential of δ-opioid receptor agonists |
| 000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
| 000C12 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 000C16 |
R. E. Gross [Canada] ; W. J. Lombardi ; W. D. Hutchison ; S. Narula ; J. A. Saint-Cyr ; J. O. Dostrovsky ; R. R. Tasker ; A. E. Lang ; A. M. Lozano | Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease : anatomical, physiological, and technical factors that determine lesion distribution |
| 000C17 |
C. R. Honey [Canada] ; A. J. Stoessl [Canada] ; J. K. C. Tsui [Canada] ; M. Schulzer [Canada] ; D. B. Calne [Canada] | Unilateral pallidotomy for reduction of parkinsonian pain |
| 000C19 |
D. A. Grimes [Canada] ; A. E. Lang | Treatment of early Parkinson's disease |
| 000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
| 000C28 |
D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada] | Ropinirole and pramipexole, the new agonists |
| 000C30 |
A. Samii [Canada] ; I. M. Turnbull [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Reassessment of unilateral pallidotomy in Parkinson's disease: A 2-year follow-up study |
| 000C31 |
P. J. Blanchet [Canada] | Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives |
| 000C36 |
A. E. Lang [Canada] ; J. Duff [Canada] ; J. A. Saint-Cyr [Canada] ; L. Trepanier [Canada] ; R. E. Gross [Canada] ; W. Lombardi [Canada] ; E. Montgomery [États-Unis] ; W. Hutchinson [Canada] ; A. M. Lozano [Canada] | Posteroventral medial pallidotomy in Parkinson's disease |
| 000C37 |
K. Kitani [Japon] ; S. Kanai [Japon] ; G. O. Ivy [Canada] ; M. C. Carrillo [Argentine] | Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl : a possible antioxidant strategy |
| 000C38 |
M. Guttman [Canada] ; O. Suchowersky [Canada] | Parkinson's disease management : Towards a new paradigm |
| 000C43 |
C. Honey [Canada] ; R. E. Gross [Canada] ; A. M. Lozano [Canada] | New developments in the surgery for Parkinson's disease |
| 000C44 |
P. Ashby [Canada] ; Y. J. Kim [Canada] ; R. Kumar [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] | Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus |
| 000C47 |
T. Mendis [Canada] ; O. Suchowersky [Canada] ; A. Lang [Canada] ; S. Gauthier [Canada] | Management of Parkinson's disease : A review of current and new therapies |
| 000C48 |
R. A. Hauser [États-Unis] ; T. B. Freeman [États-Unis] ; B. J. Snow [Canada] ; M. Nauert [États-Unis] ; L. Gauger [États-Unis] ; J. H. Kordower [États-Unis] ; C. W. Olanow [États-Unis] | Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease |
| 000C64 |
E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide |
| 000C67 |
R. Kumar [Canada] ; A. M. Lozano [Canada] ; E. Sime [Canada] ; E. Halket [Canada] ; A. E. Lang [Canada] | Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation |
| 000C70 |
J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada] | COMT inhibitors in Parkinson's disease |
| 000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
| 000C75 |
M. A. Bedard [Canada] ; B. Pillon [France] ; B. Dubois [France] ; N. Duchesne [Canada] ; H. Masson [Canada] ; Yves Agid [France] | Acute and long-term administration of anticholinergics in Parkinson's disease : Specific effects on the subcortico-frontal syndrome |
| 000C77 |
T. L. Sourkes [Canada] | "Rational hope" in the early treatment of Parkinson's disease |
| 000C78 |
A. Hadjtahar [Canada] ; P. J. Bedard [Canada] | Comprendre et traiter les dyskinésies induites par la levodopa |
| 000C92 |
A. E. Lang [Canada] ; A. M. Lozano [Canada] | Parkinson's disease : Second of two parts |
| 000C93 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; W. D. Hutchison [Canada] | Pallidotomy for tremor |
| 000C94 |
R. Kumar [Canada] ; A. M. Lozano [Canada] ; E. Montgomery [États-Unis] ; A. E. Lang [Canada] | Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease |
| 000C95 |
N. Galvez-Jimenez [Canada] ; A. Lozano [Canada] ; R. Tasker [Canada] ; J. Duff [Canada] ; W. Hutchison [Canada] ; A. E. Lang [Canada] | Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy |
| 000C96 |
L. L. Trepanier [Canada] ; J. A. Saint-Cyr [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease |
| 000C97 |
W. D. Hutchison [Canada] ; R. J. Allan [Canada] ; H. Opitz [Canada] ; R. Levy [Canada] ; J. O. Dostrovsky [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] | Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease |
| 000C99 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
| 000D00 |
A. M. Lozano [Canada] ; W. D. Hutchison [Canada] ; R. R. Tasker [Canada] ; A. E. Lang [Canada] ; F. Junn [Canada] ; J. O. Dostrovsky [Canada] | Microelectrode recordings define the ventral posteromedial pallidotomy target |
| 000D03 |
J. H. Carter [États-Unis] ; B. J. Stewart [États-Unis] ; P. G. Archbold [États-Unis] ; I. Inoue [États-Unis] ; J. Jaglin [États-Unis] ; M. Lannon [États-Unis] ; E. Rost-Ruffner [États-Unis] ; M. Tennis [États-Unis] ; M. P. Mcdermott [États-Unis] ; D. Amyot [Canada] ; R. Barter [États-Unis] ; L. Cornelius [États-Unis] ; C. Demong [Canada] ; J. Dobson [États-Unis] ; J. Duff [Canada] ; J. Erickson [États-Unis] ; N. Gardiner [États-Unis] ; L. Gauger [États-Unis] ; P. Gray [Canada] ; B. Kanigan [Canada] ; B. Kiryluk [États-Unis] ; P. Lewis [États-Unis] ; K. Mistura [États-Unis] ; T. Malapira [États-Unis] ; M. Pay [États-Unis] ; C. Sheldon [États-Unis] ; L. Winfield [États-Unis] ; K. Wolfington-Shallow [États-Unis] ; K. Zoog [États-Unis] | Living with a person who has Parkinson's disease : The spouse's perspective by stage of disease |
| 000D05 |
J. H. Growdon [États-Unis] ; K. Kieburtz [Canada] ; M. P. Mcdermott [Canada] ; M. Panisset [Canada] ; J. H. Friedman [États-Unis] | Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients |
| 000D08 |
P. Ashby [Canada] ; A. Strafella [Canada] ; J. O. Dostrovsky [Canada] ; A. Lozano [Canada] ; A. E. Lang [Canada] | Immediate motor effects of stimulation through electrodes implanted in the human globus pallidus |
| 000D12 |
P. L. Mcgeer [Canada] ; E. G. Mcgeer [Canada] | Glial cell reactions in neurodegenerative diseases : Pathophysiology and therapeutic interventions |
| 000D18 |
V. Mehta [Canada] ; M. Hong [Canada] ; J. Spears [Canada] ; I. Mendez [Canada] | Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor |
| 000D25 |
M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France] | Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist |
| 000D44 |
| Greffes |
| 000D45 |
A. Destee [France] | Données séméiologiques et principes actuels du traitement médical |
| 000D51 |
L. Thorpe [Canada] | The treatment of psychotic disorders in late life |
| 000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
| 000D63 |
A. E. Lang [Canada] ; A. M. Lozano [Canada] ; E. Montgomery [États-Unis] ; J. Duff [Canada] ; R. Tasker [Canada] ; W. Hutchinson [Canada] | Posteroventral medial pallidotomy in advanced Parkinson's disease |
| 000D68 |
P. A. Rochon [Canada] ; J. H. Gurwitz [États-Unis] | Optimising drug treatment for elderly people : the prescribing cascade |
| 000D72 |
M. Mamelak [Canada] | Neurodegeneration, sleep, and cerebral energy metabolism : A testable hypothesis |
| 000D73 |
V. Mehta [Canada] ; J. Spears [Canada] ; I. Mendez [Canada] | Neural transplantation in Parkinson's disease |
| 000D74 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; W. D. Hutchison [Canada] ; J. O. Dostrovsky [Canada] | Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease |
| 000D75 |
A. E. Lang [Canada] ; A. Lozano [Canada] ; J. Duff [Canada] ; R. Tasker [Canada] ; J. Miyasaki ; N. Galvez-Jimenez ; W. Hutchison ; J. Dostrovsky | Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration |
| 000D83 |
A. Kishore [Canada] ; I. M. Turnbull [Canada] ; B. J. Snow [Canada] ; R. De La Fuente-Fernandez [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: Six-month follow-up with additional 1-year observations |
| 000D85 |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
| 000D86 |
W. D. Hutchison [Canada] ; R. Levy [Canada] ; J. O. Dostrovsky [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Effects of apomorphine on globus pallidus neurons in parkinsonian patients |
| 000D90 |
M. Guttman [Canada] | Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease |
| 000D92 |
A. Rajput [États-Unis] ; A. Kishore [Canada] ; B. Snow [Canada] ; C. F. Bolton [Canada] ; A. H. Rajput [Canada] | Dopa-responsive, nonprogressive, juvenile parkinsonism : Report of a case |
| 000D93 |
P. W. Baures [États-Unis] ; W. H. Ojala [États-Unis] ; W. J. Costain [Canada] ; M. C. Ott [Canada] ; A. Pradhan [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide |
| 000E04 |
J. Guridi [Espagne] ; A. M. Lozano [Canada] ; J. G. Martin-Rodriguez ; L. D. Lunsford ; P. J. Kelly ; K. J. Burchiel ; R. J. Maciunas ; B. Blumenkopf ; L. V. Laitinen | A brief history of pallidotomy. Commentaries |
| 000E06 |
| |
| 000E07 |
MANOHAR LAL THAKUR [Canada] ; UMA SHANKAR SRIVASTAVA [Canada] | Vitamin-E metabolism and its application |
| 000E16 |
W. G. Tatton [Canada] ; R. M. E. Chalmers-Redman [Canada] | Modulation of gene expression rather than monoamine oxidase inhibition : (-)-Deprenyl-related compounds in controlling neurodegeneration |
| 000E19 |
A. Lozano [Canada] ; W. Hutchison ; Z. Kiss ; R. Tasker ; K. Davis ; J. Dostrovsky | Methods for microelectrode-guided posteroventral pallidotomy |
| 000E20 |
C. L. Barclay [Canada] ; J. Duff ; P. Sandor ; A. E. Lang | Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy |
| 000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 000E34 |
C. V. Borlongan [États-Unis] ; T. B. Freeman ; R. A. Hauser ; D. W. Cahill ; P. R. Sanberg ; R. R. Tasker | Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism : Relevance to neural transplantation. Commentary |
| 000E48 |
J.-A. St-Pierre [Canada] ; P. J. Bedard | Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine |
| 000E58 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
| 000E68 |
A. M. Lozano [Canada] ; A. E. Lang ; N. Galvez-Jimenez ; J. Miyasaki ; J. Duff ; W. D. Hutchinson ; J. O. Dostrovsky | Effect of GPi pallidotomy on motor function in Parkinson's disease |
| 000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
| 000E75 |
O. Suchowersky [Canada] ; S. Furtado ; G. Rohs | Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease |
| 000E82 |
| |
| 000E92 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 000F00 |
P. H. Yu [Canada] | Pharmacological and clinical implications of MAO-B inhibitors |
| 000F02 |
G. M. Guiraudon [Canada] ; C. M. Guiraudon [Canada] ; G. J. Klein [Canada] ; R. Yee [Canada] ; R. K. Thakur [Canada] | Operation for the Wolff-Parkinson-White syndrome in the catheter ablation era |
| 000F13 |
W. D. Hutchison [Canada] ; A. M. Lozano ; K. D. Davis [Canada] ; J. A. Saint-Cyr ; A. E. Lang ; J. O. Dostrovsky | Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients |
| 000F19 |
D. B. Calne [Canada] | Treatment of Parkinson's disease |
| 000F21 |
S. Weissenborn [Canada] | The effect of using a two-step verbal cue to a visual target above eye level on the Parkinsonian gait : a case study |
| 000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 000F57 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 000F61 |
| 3 rd Canadian conference on neurodegenerative diseases, L'Estérel PQ, April 4-6, 1991 |
| 000F68 |
M. Schulzer [Canada] ; E. Mark ; D. B. Calne | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
| 000F70 |
H. A. Robertson [Canada] ; M. R. Peterson ; G. G. Worth | Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243 |
| 000F71 |
A. J. Razzouk [Canada] ; R. Gow ; J. Finley ; D. Murphy ; W. G. Williams | Surgically created Wolff-Parkinson-White syndrome after fontan operation |
| 000F88 |
E. Pourcher [Canada] ; B. Gomez-Mancilla ; P. J. Bedard | Ethosuximide and tremor in Parkinson's disease : a pilot study |
| 000F89 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
| 000F91 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys |
| 000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 001006 |
M. D. Sharpe [Canada] ; W. B. Dobkowski [Canada] ; J. M. Murkin [Canada] ; G. Klein ; G. Guiraudon ; R. Yee | Alfentanil-midazolam anaesthesia has no electrophysiological effects upon the normal conduction system or accessory pathways in patients with Wolff-Parkinson-White syndrome |
| 001013 |
R. Rivest ; S. St-Pierre ; F. B. Jolicoeur | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat |
| 001025 |
R. Lemery ; TACK KI LEUNG ; E. Lavellee ; A. Girard ; M. Takajic ; D. Roy ; M. Montpetit | In vitro and in vivo effects within the coronary sinus of nonarcing an arcing shocks using a new system of low-energy DC ablation |
| 001032 |
O. S. Kofman [Canada] | Deprenyl : protective vs. symptomatic effect |
| 001046 |
P. L. Page [Canada] ; L. C. Pelletier ; W. Kaltenbrunner ; E. Vitali ; D. Roy ; R. Nadeau | Surgical treatment of the Wolff-Parkinson-White syndrome : endocardial versus epicardial approach |
| 001047 |
G. M. Guiraudon ; G. J. Klein ; R. Yee ; R. Kaushik ; D. G. Mclellan ; D. M. Cade | Surgical epicardial ablation of left ventricular pathway using sling exposure |
| 001057 |
C. J. Murdock ; G. J. Klein ; R. Yee ; J. W. Leitch | Management of the patient with the Wolff-Parkinson-White syndrome |
| 001060 |
R. Turcotte ; C. Godin ; R. Duchesne ; A. Jodoin | Hip fractures and Parkinson's disease : a clinical review of 94 fractures treated surgically |
| 001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001064 |
C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
| 001067 |
P. Seeman ; H. B. Niznik | Dopamine receptors and transporters in Parkinson's disease and schizophrenia |
| 001070 |
J. K. C. Tsui ; R. F. Peppard ; K. C. Petruk ; G. Allen ; R. S. Burns ; D. B. Calne | Decreased efficay of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants |
| 001074 |
E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
| 001075 |
A. E. Lang ; D. E. Riley ; L. Vachon ; X. Lataste | CQA 206-291 in Parkinson's disease : an acute single escalating dosage study |
| 001076 |
M. Zardini ; J. W. Leitch ; G. M. Guiraudon ; G. J. Klein ; R. Yee | Atrioventricular nodal reentry and dual atrioventricular node physiology in patients undergoing accessory pathway ablation |
| 001077 |
A. W. R. Jones ; J. S. Richardson | Alzheimer's disease : clinical and pathological characteristics |
| 001090 |
M. Guttman ; R. S. Burns ; W. R. W. Martin ; R. F. Peppard ; M. J. Adam ; T. J. Ruth ; G. Allen ; R. A. Parker ; N. B. Tulipan ; D. B. Calne | PET studies of Parkinsonian patients treated with autologous adrenal implants |
| 001100 |
E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
| 001101 |
G. J. Klein ; E. N. Prystowsky ; R. Yee ; A. D. Sharma ; A. Laupacis | Asymptomatic Wolff-Parkinson-White. Should we intervene? |
| 001102 |
O. Fujimura ; G. J. Klein ; A. D. Sharma ; R. Yee ; T. Szabo | Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome |
| 001112 |
M. Pisa | Regional specialization of motor functions in the rat striatum: implications for the treatment of parkinsonism |
| 001116 |
J. D. Grimes ; M. N. Hassan ; J. H. Thakar | Prevention of progression of Parkinson's disease with antioxidative therapy |
| 001117 |
D. Riley ; A. E. Lang | Practical application of a low-protein diet for Parkinson's disease |
| 001126 |
P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
| 001128 |
R. J. Riopelle | Adrenal medulla autografts in Parkinson's disease: a proposed mechanism of action |
| 001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 001138 |
J. A. Sharpe ; W. A. Fletcher ; A. E. Lang ; D. H. Zackon | Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease |
| 001144 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Parkinson's disease: cognitive changes in relation to treatment response |
| 001147 |
H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
| 001167 |
C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne | Sinemet in Parkinson's disease: efficacy with and without food |
| 001176 |
E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. Calne | Effect of antacid on levodopa therapy |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
| 001198 |
J. D. Grimes ; D. B. King ; O. S. Kofman ; P. Molina-Negro ; A. F. Wilson ; S. Bouchard | Bromocriptine in the management of end of dose deterioration in Parkinson's disease |
